Safety of ACE inhibitor therapies in patients with chronic kidney disease.
about
Low protein diets in patients with chronic kidney disease: a bridge between mainstream and complementary-alternative medicines?Oral Delivery of Protein Drugs Bioencapsulated in Plant CellsTolerability of Antihypertensive Medications in Older Adults.Cross-sectional investigation of drug-related problems among adults in a medical center outpatient clinic: application of virtual medicine records in the cloud.Antihypertensive effect of an enzymatic hydrolysate from Styela clava flesh tissue in type 2 diabetic patients with hypertension.Predicted Release and Analysis of Novel ACE-I, Renin, and DPP-IV Inhibitory Peptides from Common Oat (Avena sativa) Protein Hydrolysates Using in Silico Analysis.
P2860
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
@ast
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
@en
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
@nl
type
label
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
@ast
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
@en
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
@nl
prefLabel
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
@ast
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
@en
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
@nl
P2860
P1476
Safety of ACE inhibitor therapies in patients with chronic kidney disease.
@en
P2093
Gerjan Navis
P2860
P304
P356
10.1517/14740338.2014.951328
P407
P577
2014-08-22T00:00:00Z